Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DM

NCT05037045 · Completed

Last updated 2026-05-28

This clinical trial is testing how a person's genes may affect how well a type 2 diabetes medication called GLP-1 receptor agonists works in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 338 people

Who can join Ages 25–70 · all sexes

Timeline Started 2019-01 · est. completion 2024-01

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT05037045 ↗

Description as written by the study sponsor.

1. This is an prospective study to evaluate the effect of gene polymorphisms on therapeutic responses to glucagon like peptide-1 receptor agonist (GLP-1 RA) in patients with T2DM. 2. T2DM patients and healthy subjects were recruited to identify genotypes and detect the level of T2DM susceptibility genes expression levels in the plasma of healthy participants and T2DM patients. 3. This is a retrospective cohort study of patients with T2DM who were treated with exenatide twice daily as a part of their diabetes care for at least 12 months.

Treatments tested

GLP-1 receptor agonist also known as GLP-1 analogues Drug

GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months in patients with T2DM

Main thing measured	Change from baseline HbA1c at 1 month
Sponsor	The Affiliated Hospital of Xuzhou Medical University
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05037045 ↗